Effects of Dexmedetomidine on OI, RI and Inflammatory Factors in Patients Undergoing Palatopalatyngoplasty.

General Hospital of Ningxia Medical University

Status: Unknown

Conditions: Adverse Effect

Treatments: Drug: dexmedetomidine; Other: normal saline

Study type: Interventional

Funder types: Other

Identifiers

NCT03612440

MHX07

Details and patient eligibility

About

The purpose of this study is to investigate the efficacy of dexmedetomidine on oxygenation index, respiratory index and inflammatory factors, and to explore the protective effect of the dexmedetomidine on respiratory function in patients undergoing palatopalatyngoplasty.

Full description

Obstructive sleep apnea syndrome is common among people, especially among obese people, Which is characterized by periodic or complete upper airway obstruction and hypoxia during sleep. Intermittent hypoxia contributes to the lung damage by increased oxidative stress, inflammation. Some researchers suggested that dexmedetomidine can inhibit inflammatory reaction and lessen the damage of respiratory function. The aim of this study is to investigate the efficacy of dexmedetomidine on oxygenation index, respiratory index and inflammatory factors, and to explore the protective effect of the dexmedetomidine on respiratory function in patients undergoing palatopalatyngoplasty.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing palatopalatyngoplasty
• ASA physical status II-III
• Aged 18-65 years
• BMI 18.5-30kg/m2

Exclusion criteria

• Bradycardia
• Atrioventricular block
• Allergic to the drugs
• Complicating pulmonary disease(including pulmonary infection,COPD, asthma and so on)

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

80 participants in 2 patient groups, including a placebo group

Group D

Experimental group

Description:

40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery

Treatment:

Drug: dexmedetomidine

Group C

Placebo Comparator group

Description:

40 patients receive matching placebo (normal saline)

Treatment:

Other: normal saline